TargetMol

Eltoprazine dihydrochloride

Product Code:
 
TAR-T7746
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7746-5mg5mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7746-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7746-10mg10mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7746-25mg25mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7746-50mg50mg£224.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7746-100mg100mg£302.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Eltoprazine dihydrochloride is a drug that had previously been developed for aggression, has recently been investigated for L-DOPA-induced dyskinesia in animal models of Parkinson?s disease (PD) and in dyskinetic PD patients.
CAS:
143485-51-2
Formula:
C12H18Cl2N2O2
Molecular Weight:
293.19
Purity:
0.9994
SMILES:
Cl.Cl.C1CN(CCN1)c1cccc2OCCOc12

References

Keywood, Charlotte, Widner, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study[J]. Brain: A journal of neurology, 2015. Gravius A , Dekundy A , Vanaga A , et al. Further pharmacological characterization of eltoprazine: Focus on its anxiolytic, anorexic, and adverse-effect potential[J]. Acta neurobiologiae experimentalis, 2017, 77(1):77-85.